These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14970592)

  • 21. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver.
    Nakai H; Herzog RW; Hagstrom JN; Walter J; Kung SH; Yang EY; Tai SJ; Iwaki Y; Kurtzman GJ; Fisher KJ; Colosi P; Couto LB; High KA
    Blood; 1998 Jun; 91(12):4600-7. PubMed ID: 9616156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.
    Cooper M; Nayak S; Hoffman BE; Terhorst C; Cao O; Herzog RW
    Hum Gene Ther; 2009 Jul; 20(7):767-76. PubMed ID: 19309290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin Therapy Improves Adeno-Associated Virus Transduction of Liver and Skeletal Muscle in Mice and Cultured Cells.
    Carrig S; Bijjiga E; Wopat MJ; Martino AT
    Hum Gene Ther; 2016 Nov; 27(11):892-905. PubMed ID: 27358030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
    Cohn EF; Zhuo J; Kelly ME; Chao HJ
    J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
    Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
    Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle.
    Larson PJ; High KA
    Adv Exp Med Biol; 2001; 489():45-57. PubMed ID: 11554590
    [No Abstract]   [Full Text] [Related]  

  • 27. Adeno-associated virus-mediated gene transfer for hemophilia B.
    High KA
    Int J Hematol; 2002 Nov; 76(4):310-8. PubMed ID: 12463593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice.
    Koo T; Popplewell L; Athanasopoulos T; Dickson G
    Hum Gene Ther; 2014 Feb; 25(2):98-108. PubMed ID: 24191945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.
    Buchlis G; Podsakoff GM; Radu A; Hawk SM; Flake AW; Mingozzi F; High KA
    Blood; 2012 Mar; 119(13):3038-41. PubMed ID: 22271447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functions of AAV-CMV-F.IX And AAV-EF1alpha-F.IX in gene therapy for hemophilia B.
    Wiwanitkit V
    Hum Gene Ther; 2007 Feb; 18(2):89-92. PubMed ID: 17266422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer.
    Cordier L; Hack AA; Scott MO; Barton-Davis ER; Gao G; Wilson JM; McNally EM; Sweeney HL
    Mol Ther; 2000 Feb; 1(2):119-29. PubMed ID: 10933922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
    Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
    Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transduction Efficiency of Adeno-Associated Virus Serotypes After Local Injection in Mouse and Human Skeletal Muscle.
    Muraine L; Bensalah M; Dhiab J; Cordova G; Arandel L; Marhic A; Chapart M; Vasseur S; Benkhelifa-Ziyyat S; Bigot A; Butler-Browne G; Mouly V; Negroni E; Trollet C
    Hum Gene Ther; 2020 Feb; 31(3-4):233-240. PubMed ID: 31880951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability.
    Gonçalves MA; van Nierop GP; Tijssen MR; Lefesvre P; Knaän-Shanzer S; van der Velde I; van Bekkum DW; Valerio D; de Vries AA
    J Virol; 2005 Mar; 79(5):3146-62. PubMed ID: 15709034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective uptake and sustained expression of AAV vectors following subcutaneous delivery.
    Donahue BA; McArthur JG; Spratt SK; Bohl D; Lagarde C; Sanchez L; Kaspar BA; Sloan BA; Lee YL; Danos O; Snyder RO
    J Gene Med; 1999; 1(1):31-42. PubMed ID: 10738583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
    Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
    J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.
    Fraefel C; Jacoby DR; Lage C; Hilderbrand H; Chou JY; Alt FW; Breakefield XO; Majzoub JA
    Mol Med; 1997 Dec; 3(12):813-25. PubMed ID: 9440115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
    Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
    Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
    Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
    Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.